Statin safety

Statin safety project: open for out-licensing and/or co-depelopment

Scientific background:

• We have previously shown that statins interfere with the endogenous cardioprotective mechanism of pre- and postconditioning, thereby producing an occult cardiotoxicity (Am J Physiol Heart Circ Physiol. 294:H2406-9, 2008; Pharmacol Rev, 59:418-58, 2007)

Summary of invention:

• Endogenous substance to inhibit a side effect of statins to reduce endogenous cardioprotection.

IP status:

• Patented technology (primary filing date May, 2012)

Potential investors and/or co-development partners,

please contact us for further details at

(Please manually type the e-mail address in your e-mail client.)